[go: up one dir, main page]

WO1999009965A3 - Agent antiinflammatoire - Google Patents

Agent antiinflammatoire Download PDF

Info

Publication number
WO1999009965A3
WO1999009965A3 PCT/JP1998/003692 JP9803692W WO9909965A3 WO 1999009965 A3 WO1999009965 A3 WO 1999009965A3 JP 9803692 W JP9803692 W JP 9803692W WO 9909965 A3 WO9909965 A3 WO 9909965A3
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
group
inflammatory agent
formula
ring
Prior art date
Application number
PCT/JP1998/003692
Other languages
English (en)
Other versions
WO1999009965A2 (fr
Inventor
Hiroyuki Odaka
Yu Momose
Original Assignee
Takeda Chemical Industries Ltd
Hiroyuki Odaka
Yu Momose
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd, Hiroyuki Odaka, Yu Momose filed Critical Takeda Chemical Industries Ltd
Priority to AU87479/98A priority Critical patent/AU8747998A/en
Priority to EP98938913A priority patent/EP1007038A2/fr
Priority to CA002300813A priority patent/CA2300813A1/fr
Publication of WO1999009965A2 publication Critical patent/WO1999009965A2/fr
Publication of WO1999009965A3 publication Critical patent/WO1999009965A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un agent anti-inflammatoire qui modifie, par une action inhibant TNF-α et qui comprend un composé de formule (I), dans laquelle R représente un groupe hydrocarbure qui peut être substitué ou un groupe hétérocyclique qui peut être substitué; Y représente un groupe de formule -CO-, CH(OH)-, ou -NR3-, R3 représentant un groupe alkyle qui peut être substitué; m vaut 0 ou 1; n vaut 0, 1 ou 2; X représente CH ou N; A représente une liaison chimique ou un groupe hydrocarbure aliphatique ayant 1 à 7 atomes de carbone; Q représente oxygène ou soufre; R1 représente hydrogène ou un groupe alkyle; le cycle E peut comporter de plus 1 à 4 substituants, qui peuvent former un cycle en combinaison avec R1; L et M représentent respectivement hydrogène ou peuvent être combinés l'un à l'autre pour former une liaison chimique; ou un sel de celui-ci.
PCT/JP1998/003692 1997-08-21 1998-08-20 Agent antiinflammatoire WO1999009965A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU87479/98A AU8747998A (en) 1997-08-21 1998-08-20 Anti-inflammatory agent
EP98938913A EP1007038A2 (fr) 1997-08-21 1998-08-20 Agent antiinflammatoire
CA002300813A CA2300813A1 (fr) 1997-08-21 1998-08-20 Agent antiinflammatoire

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP22530297 1997-08-21
JP9/225302 1997-08-21

Publications (2)

Publication Number Publication Date
WO1999009965A2 WO1999009965A2 (fr) 1999-03-04
WO1999009965A3 true WO1999009965A3 (fr) 1999-05-20

Family

ID=16827222

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1998/003692 WO1999009965A2 (fr) 1997-08-21 1998-08-20 Agent antiinflammatoire

Country Status (4)

Country Link
EP (1) EP1007038A2 (fr)
AU (1) AU8747998A (fr)
CA (1) CA2300813A1 (fr)
WO (1) WO1999009965A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7364736B2 (en) 2001-06-26 2008-04-29 Amgen Inc. Antibodies to OPGL
US8950405B2 (en) 2006-05-15 2015-02-10 Tearscience, Inc. Treatment of obstructive disorders of the eye or eyelid
US9060843B2 (en) 2005-07-18 2015-06-23 Tearscience, Inc. Method and apparatus for treating gland dysfunction employing heated medium
US9314369B2 (en) 2006-05-15 2016-04-19 Tearscience, Inc. System for inner eyelid treatment of meibomian gland dysfunction

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2384194A1 (fr) 1999-08-31 2001-03-08 David P. M. Pleynet Benzylidene-thiazolidinediones et analogues et leur utilisation pour le traitement de l'inflammation
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
CA2399463A1 (fr) * 2000-02-10 2001-08-16 Takeda Chemical Industries, Ltd. Combinaison de medicament
WO2001062238A2 (fr) * 2000-02-24 2001-08-30 San Diego State University Procede servant a traiter des maladies du foie associees a la fonction hepatique
IL157740A0 (en) 2001-03-07 2004-03-28 Incyte San Diego Inc Heterocyclic derivatives and pharmaceutical compositions containing the same
CA2473156A1 (fr) 2001-03-08 2002-09-19 Incyte San Diego, Inc. Molecules activant un recepteur rxr
JP2005513026A (ja) 2001-11-15 2005-05-12 インサイト サン ディエゴ インコーポレイテッド 高コレステロール血症、異脂肪血症および他の代謝障害；癌、および他の疾患を治療するｎ−置換複素環
GB0128138D0 (en) * 2001-11-23 2002-01-16 King S College London Pharmaceutical use
US7102000B2 (en) 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
WO2008027069A1 (fr) 2006-08-21 2008-03-06 Tearscience, Inc. Procédé et appareil de traitement du dysfonctionnement de la glande de meibomius au moyen d'un fluide
EP3744391B1 (fr) 2013-04-30 2023-03-01 Alcon Inc. Systèmes de traitement de maladies oculaires
US9763827B2 (en) 2013-04-30 2017-09-19 Tear Film Innovations, Inc. Systems and methods for the treatment of eye conditions
US10974063B2 (en) 2016-06-30 2021-04-13 Alcon Inc. Light therapy for eyelash growth

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995035108A1 (fr) * 1994-06-22 1995-12-28 The Regents Of The University Of California Derives de thiazolidine pour le traitement du psoriasis
WO1996024350A1 (fr) * 1995-02-10 1996-08-15 Schering Aktiengesellschaft Preparations pharmaceutiques d'inhibition du facteur de necrose des tumeurs (tnf)
WO1996034943A1 (fr) * 1995-05-04 1996-11-07 City Of Hope 12-lipoxygenase leucocytaire humaine et son role dans la pathogenese d'etats pathologiques
DE19540475A1 (de) * 1995-10-20 1997-04-24 Schering Ag Chirale Methylphenyloxazolidinone
WO1997037688A2 (fr) * 1996-04-05 1997-10-16 Takeda Chemical Industries, Ltd. Combinaison pharmaceutique comprenant un compose contenant de l'angiotensine ii et presentant une activite antagoniste
WO1997045141A1 (fr) * 1996-05-31 1997-12-04 Sankyo Company, Limited Remede pour maladies auto-immunes

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995035108A1 (fr) * 1994-06-22 1995-12-28 The Regents Of The University Of California Derives de thiazolidine pour le traitement du psoriasis
WO1996024350A1 (fr) * 1995-02-10 1996-08-15 Schering Aktiengesellschaft Preparations pharmaceutiques d'inhibition du facteur de necrose des tumeurs (tnf)
WO1996034943A1 (fr) * 1995-05-04 1996-11-07 City Of Hope 12-lipoxygenase leucocytaire humaine et son role dans la pathogenese d'etats pathologiques
DE19540475A1 (de) * 1995-10-20 1997-04-24 Schering Ag Chirale Methylphenyloxazolidinone
WO1997037688A2 (fr) * 1996-04-05 1997-10-16 Takeda Chemical Industries, Ltd. Combinaison pharmaceutique comprenant un compose contenant de l'angiotensine ii et presentant une activite antagoniste
WO1997045141A1 (fr) * 1996-05-31 1997-12-04 Sankyo Company, Limited Remede pour maladies auto-immunes

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
C. HOFMANN ET AL.: "Altered Gene Expression for Tumor Necrosis Factor-alpha and Its Receptors during Drug and Dietary Modulation of Insulin Resistance", ENDOCRINOLOGY, vol. 134, no. 1, January 1994 (1994-01-01), pages 264 - 270, XP002094464 *
D.SZALKOWSKI ET AL.: "Antidiabetic Thiazolidinediones Block the Inhibitory Effect of Tumor Necrosis Factor-alpha on Differentiation, Insulin-Stimulated Glucose Uptake, and Gene Expression in 3T3-L1 Cells", ENDOCRINOLOGY, vol. 136, no. 4, April 1995 (1995-04-01), pages 1474 - 1481, XP002094465 *
H.ODAKA ET AL.: "EFFECT OF PIOGLITAZONE ON SUCROSE-DETERIORATED DIABETIC STATES IN SPONTANEOUSLY DIABETIC GK RATS", DIALOG(R) FILE 5: BIOSIS PREVIEWS(R) ACCESSION NUMBER 07798952: J. JPN. DIABETES SOC., vol. 34, no. 6, 1991, pages 523 - 530, XP002094468 *
M. SUZUKI ET AL.: "Nephropathy in genetically obese-diabetic Wistar fatty rats - Characterization and prevention", DIALOG(R) FILE 73: EMBASE, ACCESSION NUMBER 07010090: JPN. PHARMACOL. THER., vol. 25, no. 2, 1997, pages 43 - 51, XP002094469 *
P. PERALDI ET AL.: "Thiazolidinediones Block Tumor Necrosis Factor-alpha.induced Inhibition of Insulin Signaling", J. CLIN.INVEST., vol. 100, no. 7, 1 October 1997 (1997-10-01), pages 1863 - 1869, XP002094470 *
R.W.STEVENSON ET AL.: "The thiazolidinedione drug series", THE DIABETES ANNUAL, vol. 9, 1995, pages 175 - 191, XP002094463 *
S.L. GROSSMAN ET AL.: "Mechanisms and clinical effects of thiazolidinediones", EXPERT OPIN. INVEST. DRUGS, vol. 6, no. 8, August 1997 (1997-08-01), pages 1025 - 1040, XP002094471 *
S.S.SOLOMON ET AL.: "Pioglitazone and Metformin Reverse Insulin Resistance Induced by Tumor Necrosis Factor-Alpha in Liver Cells", HORMON. METAB. RES., vol. 29, no. 8, August 1997 (1997-08-01), pages 379 - 382, XP002094467 *
T. YOSHIMOTO ET AL.: "Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats", AM.J.PHYSIOL., vol. 272, no. 6 Part 1, June 1997 (1997-06-01), pages E989 - E996, XP002094466 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7364736B2 (en) 2001-06-26 2008-04-29 Amgen Inc. Antibodies to OPGL
US9060843B2 (en) 2005-07-18 2015-06-23 Tearscience, Inc. Method and apparatus for treating gland dysfunction employing heated medium
US8950405B2 (en) 2006-05-15 2015-02-10 Tearscience, Inc. Treatment of obstructive disorders of the eye or eyelid
US9314369B2 (en) 2006-05-15 2016-04-19 Tearscience, Inc. System for inner eyelid treatment of meibomian gland dysfunction

Also Published As

Publication number Publication date
WO1999009965A2 (fr) 1999-03-04
AU8747998A (en) 1999-03-16
EP1007038A2 (fr) 2000-06-14
CA2300813A1 (fr) 1999-03-04

Similar Documents

Publication Publication Date Title
WO1999009965A3 (fr) Agent antiinflammatoire
AU1172999A (en) Novel apoptosis inhibitors
CA2116387A1 (fr) Derives d'oxazolidinedione, leur production et leur utilisation
AU3461697A (en) Heterocyclic compounds, their production and use
WO1999042456A3 (fr) Nouveaux composes et leur utilisation comme modulateurs positifs du recepteur ampa
EP0513387A4 (en) Active oxygen inhibitor
CA2054209A1 (fr) Composes ureiques antihyperlipidemiques et antiatherosclereux
MY118904A (en) 4-oxo-1, 4-dihydro-3-quinolinecarboxamides as antiviral agents
UA41290C2 (uk) Гетероариламіни, фармацевтична композиція, спосіб інгібування холінестерази у ссавців, спосіб покращення пам'яті
EA200100310A1 (ru) Кислородсодержащие гетероциклические соединения
WO2003035620A1 (fr) Compose bicyclique
EP0945764A3 (fr) Composition pour photoréserve
CA2314564A1 (fr) Derives de phosphonocephem, leur procede de preparation et leur utilisation
CA2014490A1 (fr) Composes de type diaminoethylene
CA2125549A1 (fr) Derives tetrazoles, leur production et leur utilisation
WO2002000638A8 (fr) Nouveaux phthalides substitues, leur procede de preparation et compositions pharmaceutiques les contenant
IE851734L (en) Isoindolinyl-alkyl-piperazines
TW324009B (en) Pyrazole condensation ring derivative, its production process and its use as androgen inhibitor
CA2128093A1 (fr) Derives 4-aryl-3-(heteroarylureido)-1,2-dihydro-2-oxoquinoline utilisables comme agents de lutte contre l'hypercholesterolemie et l'atherosclerose
CA2247946A1 (fr) Composition anticachexique
EP0601191A4 (en) Novel tetracyclic compound.
EP0516860A4 (en) Chromone derivative and aldose reductase inhibitor containing the same as active ingredient
IE44180L (en) Azaprostaglandins.
WO2003057215A1 (fr) Accelerateur de production/secretion de facteur neurotrophique
IE45092L (en) Carbamic acid oxime-esters.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HR HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HR HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1998938913

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09485640

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2300813

Country of ref document: CA

Ref country code: CA

Ref document number: 2300813

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWP Wipo information: published in national office

Ref document number: 1998938913

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998938913

Country of ref document: EP